BioSpace News Archive

On Monday, the House Republican resigned his congressional seat ahead of the expected plea.

Stevenage Bioscience Catalyst (SBC) has announced the appointment of two new Non-Executive Directors (NEDs) to its Board.

The U.S. Food and Drug Administration (FDA) rejected the company’s inhaled triple-combination therapy, PT010, now known as Breztri Aerosphere.

The opportunity to do interesting and meaningful work continues to be more valuable than money, according to more than 2,700 life science professionals who took BioSpace’s 2019 Ideal Employer survey.

Following Purdue Pharma’s Chapter 11 filing last month, other opioid makers are exploring ways to settle their own litigation problems by participating in the OxyContin drugmaker’s bankruptcy proceedings.

The tips that follow will help you make the most of your relationship with recruiters, also known as headhunters and search firms.

TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO® was 2.7 months Compared to 1.4 Months with Placebo

Sareum Holdings plc is pleased to announce that it will present new preclinical data from its SDC-1802 TYK2/JAK1 inhibitor cancer research programme at the American Association for Cancer Research National Cancer Institute European Organisation for Research and Treatment of Cancer International Conference, to be held 26-30 October 2019 in Boston, USA.

Data shared in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)

Novo Seeds, the company creation team of Novo Holdings, announced that it has co-led the €20 million Series A financing round in STipe Therapeutics (STipe).